Atropine plus omeprazole for acute gastritis: Efficacy and safety analysis

This article primarily discusses the efficacy and safety of atropine (ATR) plus omeprazole (OME) for the treatment of acute gastritis (AG). From May 2022 to May 2024, 95 AG patients were selected, including 50 cases treated with ATR+OME (observation group) and 45 cases with anisodamine (ADM) plus OME (control group). Comparative analyses of the following dimensions were then carried out: Clinical efficacy, safety (xerostomia, palpitations, and headaches), symptom remission time (stomach pain, abdominal distension and nausea and vomiting), serum inflammatory factors (tumor necrosis factor [TNF]-?, interleukin [IL]-6 and interferon [IFN]-?) and plasma gastrointestinal hormones (epidermal growth factor [EGF], gastrin [GAS] and somatostatin [SS]). After analysis, the observation group had a higher total effective rate, a lower overall incidence of adverse reactions and a shorter remission time of symptoms such as stomach pain, abdominal distension, and nausea and vomiting than the control group, all with statistical significance. Moreover, compared with the baseline (before medication) and the control group, TNF-?, IL-6, IFN-? and GAS were reduced statistically in the observation group after medication, while EGF and SS were markedly increased. Thus, ATR plus OME has significant efficacy in the treatment of AG while ensuring high clinical safety, which deserves clinical promotion.